9-([2-Hydroxy-l-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) is more potent and has a more prolonged inhibitory effect against Epstein-Barr virus (EBV) in vitro than does acyclovir (ACV). To assess the mechanism of this difference, we first compared the extent of phosphorylation of the two drugs in superinfected Raji cells. BW B759U is phosphorylated to levels 100-fold higher than is ACV. In addition, lower levels of phosphorylation of BW B759U and ACV were observed in uninfected Raji cells. Studies on the kinetics of formation of BW B759U triphosphate in superinfected Raji cells indicated that drug-phosphorylating activity was detected as early as 3 h after superinfection; this activity was steadily maintained for the first 7 h, followed by a burst of activity between 7 and 10 h and a doubling of phosphorylation between 10 and 25 h. During the superinfection cycle, the pool sizes of deoxyribonucleoside and ribonucleoside triphosphates were increased and reached their maxima at 10 h after infection. polymerase.
9-([2-Hydroxy-l-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) is more potent and has a more prolonged inhibitory effect against Epstein-Barr virus (EBV) in vitro than does acyclovir (ACV). To assess the mechanism of this difference, we first compared the extent of phosphorylation of the two drugs in superinfected Raji cells. BW B759U is phosphorylated to levels 100-fold higher than is ACV. In addition, lower levels of phosphorylation of BW B759U and ACV were observed in uninfected Raji cells. Studies on the kinetics of formation of BW B759U triphosphate in superinfected Raji cells indicated that drug-phosphorylating activity was detected as early as 3 h after superinfection; this activity was steadily maintained for the first 7 h, followed by a burst of activity between 7 and 10 h and a doubling of phosphorylation between 10 and 25 h. During the superinfection cycle, the pool sizes of deoxyribonucleoside and ribonucleoside triphosphates were increased and reached their maxima at 10 h after infection. The maximal amount of triphosphorylated drug in a virus producer cell, P3HR-1 (LS), was polymerase.
An acyclovir (ACV) congener, 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U or DHPG), is active in vitro against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), Epstein-Barr virus (EBV), and human cytomegalovirus (5, 9, (17) (18) (19) 23) . We recently demonstrated that BW B759U has more-prolonged effects than ACV in suppressing EBV replication, even after the drug is removed from persistently infected cell cultures (17) . We have also reported preliminary evidence that BW B759U is more efficiently phosphorylated than ACV in EBV-infected cells (13) . The initial step in the antiviral action of BW B759U against HSV evidently involves its selective phosphorylation in infected cells (1, 23) , and the herpesvirusspecified DNA polymerase is subsequently inhibited by the drug 5'-triphosphate (10, 12, 24) .
To understand the molecular mechanisms of prolonged inhibition of EBV replication by BW B759U, we studied the extent of phosphorylation of this drug in superinfected Raji cells and in a virus-producing cell line, P3HR (Fig. 1) ; this activity was steadily maintained for the first 7 h. Between 7 and 10 h a rapid elevation of the BW B759U-TP level occurred, followed by a doubling of the BW B759U-TP level between 10 and 25 h postinfection. The concentration at 25 h was 20-fold greater than at 3 h after infection. These results clearly indicate that BW B759U-TP accumulated in infected cells as a function of exposure time to the drug during this phase of the superinfection cycle.
Deoxyribonucleoside and ribonucleoside triphosphate levels in superinfected Raji cells in the presence of BW B759U. In parallel with the kinetics experiment depicted in Fig. 1 , we measured the change in pool sizes of deoxyribonucleoside and ribonucleoside triphosphates during the infection cycle. Superinfection of Raji cells resulted in a severalfold increase in deoxyribonucleotide pools, with dTTP reaching the highest concentration. The pool levels increased steadily up to 9 h, and a maximum occurred between 9 and 24 h after infection for all of the pools (Fig. 2) . Ribonucleoside triphosphate pool sizes were also measured. The levels of the ribonucleoside triphosphates CTP, UTP, ATP, and GTP increased similarly with time during the infection cycle (Table 2) . CTP, UTP, and ATP levels increased approximately threefold, but the GTP level changed only slightly. Treatment of superinfected Raji cells with BW B759U does not cause changes in deoxyribonucleoside and ribonucleoside triphosphate pool levels over the changes caused by infection alone (data not shown).
Determination of optimum duration of drug treatment. To gain insight into the persistent effect of BW B759U in inhibition of EBV genome replication in P3HR-1 (LS) cells (17), we first determined the optimum duration of drug treatment that produced maximum amounts of BW B759-TP. The phosphorylated drug can be detected as early as 4 h after drug addition at 30 ,uM; the maximum formation of drug triphosphate occurred at 21 h (Fig. 3B) . At the same times, the levels of deoxyribonucleoside triphosphates were below the limits of detection by HPLC (less than 2 pmol/106 cells). The effect of the drug on EBV genome replication is shown in Fig. 3A . No significant difference in EBV genome copies per cell was observed 1 day after drug treatment. Approximately 44 and 77% reduction in EBV genome copies per cell was observed on days 3 and 7, respectively, probably owing to cell division and elimination of productive cell populations.
Persistent presence of BW B759U-TP in P3HR-1 (LS) cells after drug removal. The levels of drug triphosphate at various times after drug removal were examined. Approximately 4.2 pmoles of BW B759U-TP per 106 cells was achieved after 36 h of treatment with the drug at 100 ,uM (Fig. 4) . After the cells had been washed and released into drug-free medium, the initial drop of drug triphosphate level was very rapid, down to 11% of the original level after 1 day. Thereafter, the decrease was slow but steady, and the intracellular concentration of BW B759U-TP reached 0.22 pmol/106 cells by 5 days. 
DISCUSSION
In a previous study, we demonstrated that BW B759U is more potent and has a more prolonged inhibitory effect than ACV against EBV (17) . In that study, however, we did not elucidate the molecular mechanism underlying this difference. As for other nucleoside analogs, it has been postulated that BW B759U might be preferentially phosphorylated in EBV-infected cells in contrast to the low level of phosphorylation in uninfected cells (2, 9, 22) . Our results support this premise and show that ACV is very inefficiently phosphorylated in EBV-infected cells. The more efficient phosphorylation of BW B759U than of ACV has been observed in HSV-and cytomegalovirus-infected cells as well (2, 12) .
In wild-type HSV- (Fig. 1 ). It appears that the triphosphate of BW B759U, once formed, is relatively stable and is conserved within the cells.
There is some evidence against the existence of an EBVspecific thymidine kinase (7, 21) . However, other evidence indicates that there is a novel enzyme activity induced by EBV that might represent a virally encoded thymidine kinase (3, 20, 25) . Despite these discrepancies, we found that BW B759U, in contrast to ACV, is preferentially phosphorylated in superinfected Raji cells compared with mockinfected cells. Whether the low level of phosphorylation of BW B759U in mock-infected cells is carried out by the same enzyme as in superinfected Raji cells remains to be determined.
The level of BW B759U-TP that was achieved in P3HR-1 (LS) cells after 36 h of treatment with the drug at 100 ,uM was 4.2 pmol/106 cells (Fig. 3) , which is low compared with that achieved in superinfected Raji cells with less drug and shorter times. On the basis of the measured cell volume, 1 iuiI106 cells, we calculated that the initial concentration of BW B759U-TP in the P3HR-1 (LS) cells was 4.2 ,uM before drug removal and 0.22 ,uM 5 days after drug removal. These concentrations were sufficient to inhibit EBV replication, compared with the 50% effective dose of BW B759U (0.05 ,uM) for the inhibition of EBV genome replication (17) and with the Ki (0.08 ,uM) of BW B759U-TP for EBV DNA polymerase (6) . On the basis of the rate of decrease of the BW B759U-TP level in the cells between days 1 and 5 after drug removal (Fig. 4) , we predict that it would have taken more than 2 weeks for the BW B759U-TP to diminish below the concentration required for effective inhibition (<0.08 ,uM) of the EBV polymerase. The persistence of BW B759U-TP in P3HR-1 (LS) cells for 5 days after drug removal may account for the prolonged inhibitory effect of BW B759U observed previously (17) .
In contrast with ACV, which is a chain terminator only (8) When dGTP is low, as in P3HR cells (unpublished data), the levels of BW B759U-TP described in this experiment should be able to compete for incorporation into EBV DNA. These metabolic results could add to the more prolonged inhibition of EBV by BW B759U than by ACV.
